Agilon Health Notified of Noncompliance by NYSE
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 07 2025
0mins
Should l Buy AGL?
- Compliance Notice: Agilon Health received a notice from the New York Stock Exchange on November 5 regarding non-compliance with listing standards.
- Stock Price Issue: The company's common stock averaged less than $1.00 per share over a consecutive 30 trading-day period ending November 4.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AGL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AGL
Wall Street analysts forecast AGL stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.354
Low
0.88
Averages
0.88
High
0.88
Current: 0.354
Low
0.88
Averages
0.88
High
0.88
About AGL
agilon health, inc. is a healthcare company. It enables primary care physicians (PCP) to be the agents for change in the communities they serve. Through its combination of the agilon platform, a long-term partnership model with existing physician groups and a growing network of like-minded physicians, it offers healthcare for seniors across communities throughout the United States. Its model operates by primarily forming risk-bearing entities (RBEs) within local geographies, that enter into arrangements with payors providing for monthly payments to manage the total healthcare needs of its physician partners’ attributed patients (or global capitation arrangements). It focuses on community-based physician groups and is built around three key elements: agilon’s platform, agilon’s long-term physician partnership approach, and agilon’s network. The agilon platform is holistic in supporting the rapid transition to a Total Care Model with technology, people, process and capital.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Class Action Notice: The Gross Law Firm has issued a notice to shareholders of Agilon Health, encouraging those who purchased AGL shares between February 26, 2025, and August 4, 2025, to contact the firm regarding possible lead plaintiff appointment for potential recovery.
- Allegations of False Statements: The complaint alleges that during the class period, defendants made materially false and/or misleading statements and failed to disclose significant industry headwinds that would impact their 2025 guidance, misleading shareholders about the company's prospects.
- Overstated Financial Impact: Defendants are accused of materially overstating the immediate positive financial impact of strategic actions taken by Agilon, which misled shareholders and harmed their investment decisions.
- Registration Deadline: Shareholders must register by March 2, 2026, to participate in the class action, and upon registration, they will receive status updates throughout the case lifecycle, ensuring their rights are protected.
See More
- Class Action Overview: The Law Offices of Frank R. Cruz remind investors that class action lawsuits have been filed against companies including agilon health, Fermi Inc., Varonis Systems, and Ardent Health, with deadlines for lead plaintiff motions approaching.
- agilon health Allegations: From February 26 to August 4, 2025, agilon health is accused of making materially false statements regarding its financial guidance, failing to disclose industry headwinds, which misled investors about the company's prospects, with a lead plaintiff deadline of March 2, 2026.
- Fermi Inc. Lawsuit Details: Fermi Inc. is charged with overstating tenant demand and the reliance on a single tenant's funding for its Project Matador from October 1 to December 11, 2025, with a lead plaintiff deadline of March 6, 2026.
- Varonis and Ardent Issues: Varonis is accused of being ill-equipped to sustain its ARR growth from February 4 to October 28, 2025, while Ardent is charged with failing to accurately assess the collectability of accounts receivable from July 18, 2024, to November 12, 2025, with lead plaintiff deadlines of March 9, 2026, for both companies.
See More
- Lawsuit Background: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Agilon Health, Inc. on behalf of investors who purchased securities between February 26, 2025, and August 4, 2025, alleging that the company made false and misleading statements during this period, resulting in investor losses.
- Allegation Details: The lawsuit claims that Agilon executives issued unrealistic 2025 financial guidance despite being aware of significant industry challenges, and materially overstated the positive financial impact of their strategic actions, leading to a severely distorted view of the company's business and prospects among investors.
- Investor Rights: Affected investors must apply by March 2, 2026, to be appointed as lead plaintiffs in the lawsuit to protect their legal rights, with Bragar Eagel & Squire offering free consultations and encouraging investors to reach out for more information.
- Law Firm Overview: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in representing individual and institutional investors in securities, derivative, and commercial litigation, boasting extensive litigation experience and a nationwide practice.
See More
- Class Action Initiated: Robbins LLP reminds shareholders that a class action has been filed on behalf of investors who purchased Agilon Health (NYSE: AGL) securities between February 26, 2025, and August 4, 2025, alleging the company failed to disclose significant risks to its business prospects.
- Misleading Financial Guidance: The complaint alleges that Agilon Health issued optimistic financial guidance for 2025 despite being aware of substantial industry headwinds, misleading investors and overstating the positive impact of strategic actions taken to mitigate risks.
- Executive Departure Impact: On August 4, 2025, Agilon announced the resignation of CEO Steven Sell, and the subsequent disappointing financial results led to a stock price drop of over 50% to close at $0.8801 on August 5, 2025, significantly impacting investor confidence.
- Call to Action for Shareholders: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by March 2, 2026, while those who choose not to participate can remain absent class members and still retain their rights to recovery.
See More
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Agilon Health, alleging violations of federal securities laws on behalf of all investors who purchased Agilon securities between February 26, 2025, and August 4, 2025.
- False Statement Allegations: The complaint claims that Agilon executives issued unrealistic 2026 financial guidance despite being aware of significant industry headwinds, while also overstating the immediate financial benefits of strategic actions taken, misleading investors throughout the class period.
- Investor Actions: Affected investors are encouraged to apply to be lead plaintiffs by March 2, 2026, to share in any potential recovery from the lawsuit, with the option to participate without being the lead plaintiff.
- Law Firm's Advantage: Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm specializing in securities fraud class actions, having recovered hundreds of millions for investors, emphasizing their commitment to restoring investor capital and ensuring corporate accountability.
See More
- Leadership Change: Agilon Health announced on August 4, 2025, that CEO Steven Sell stepped down, raising concerns about the company's future and leading to a decline in investor confidence.
- Guidance Withdrawal: Concurrently with the leadership transition, Agilon Health withdrew its full-year 2025 earnings guidance, indicating uncertainty about future performance, which may affect investor decision-making.
- Stock Price Plunge: Following the announcement, Agilon Health's shares fell over 27% in after-hours trading, reflecting a pessimistic outlook from the market and potentially prompting more investors to seek legal recourse.
- Legal Investigation Initiated: DJS Law Group is investigating whether Agilon Health made misleading statements or failed to disclose critical information, aiming to protect investor rights and pursue potential compensation.
See More







